First-in-Human Study of MDG1011, a TCR-T Therapy Directed Against HLA-A*02:01-Restricted PRAME Antigen for High-Risk Myeloid and Lymphoid Neoplasms.

Thomas S, Wermke M, Vučinić V, Wagner-Drouet E, Mackensen A, Zeiser R, Bug G, Schmitt M, Herr W, Prinz PU, Bürdek M, Raffegerst S, Tafuri A, Geiger C, Crame K, Goedkoop R, Pinkernell K, Schendel DJ

Open source

DOI: 10.3390/cancers17182968
Published: 2025 Sep 11
Container: Cancers
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3390/cancers17182968,
  title = {First-in-Human Study of MDG1011, a TCR-T Therapy Directed Against HLA-A*02:01-Restricted PRAME Antigen for High-Risk Myeloid and Lymphoid Neoplasms.},
  author = {Thomas S and Wermke M and Vučinić V and Wagner-Drouet E and Mackensen A and Zeiser R and Bug G and Schmitt M and Herr W and Prinz PU and Bürdek M and Raffegerst S and Tafuri A and Geiger C and Crame K and Goedkoop R and Pinkernell K and Schendel DJ},
  year = {2025},
  journal = {Cancers},
  doi = {10.3390/cancers17182968},
  url = {https://doi.org/10.3390/cancers17182968}
}

RIS

TY  - JOUR
TI  - First-in-Human Study of MDG1011, a TCR-T Therapy Directed Against HLA-A*02:01-Restricted PRAME Antigen for High-Risk Myeloid and Lymphoid Neoplasms.
AU  - Thomas S
AU  - Wermke M
AU  - Vučinić V
AU  - Wagner-Drouet E
AU  - Mackensen A
AU  - Zeiser R
AU  - Bug G
AU  - Schmitt M
AU  - Herr W
AU  - Prinz PU
AU  - Bürdek M
AU  - Raffegerst S
AU  - Tafuri A
AU  - Geiger C
AU  - Crame K
AU  - Goedkoop R
AU  - Pinkernell K
AU  - Schendel DJ
PY  - 2025
JO  - Cancers
DO  - 10.3390/cancers17182968
UR  - https://doi.org/10.3390/cancers17182968
ER  -

APA

S, T., M, W., V, V., E, W., A, M., R, Z., G, B., M, S., W, H., PU, P., M, B., S, R., A, T., C, G., K, C., R, G., K, P., & DJ, S. (2025). First-in-Human Study of MDG1011, a TCR-T Therapy Directed Against HLA-A*02:01-Restricted PRAME Antigen for High-Risk Myeloid and Lymphoid Neoplasms.. Cancers. https://doi.org/10.3390/cancers17182968

Source records

pubmed · retrieved 2026-09-26T04:43:46.502Z